scholarly journals Demographic and Clinical Factors Associated With the Appropriate Target Thyroid-Stimulating Hormone Values in Patients With Primary Hypothyroidism Treated With Levothyroxine

2016 ◽  
Vol 6 (4) ◽  
pp. 109-115
Author(s):  
Lara Moreira Baptista de Sousa ◽  
Elisa Baranski Lamback ◽  
Thomaz Schroder Lameirinhas ◽  
Michelle Botelho Caarls ◽  
Leonardo Vieira Neto
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Clinical Factors ◽  
Factors Associated ◽  
Stimulating Hormone

scholarly journals Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy

2019 ◽  
Vol 8 (9) ◽  
pp. 1279 ◽  
Author(s):  
Lee ◽  
Jeon ◽  
Kim ◽  
Sung ◽  
Chung ◽  
...  
Keyword(s):  
Success Rate ◽  
Associated Factors ◽  
Clinical Characteristics ◽  
Clinical Results ◽  
Thyroid Stimulating Hormone ◽  
Low Risk ◽  
Maintenance Period ◽  
Papillary Thyroid ◽  
Clinical Factors ◽  
Factors Associated

Background: This study aimed to identify the clinical results after thyrotropin suppression therapy (TST) cessation and evaluated clinical factors associated with successful TST cessation. Methods: Patients who underwent lobectomy due to low-risk papillary thyroid carcinoma (PTC) were included in this study. We compared clinical characteristics and outcomes between patients who succeeded to stop TST and failed to stop TST. Results: A total of 363 patients were included in the study. One hundred and ninety-three patients (53.2%, 193/363) succeeded to stop TST. The independent associated factors for successful TST cessation were the preoperative thyroid-stimulating hormone (TSH) level and the maintenance period of TST. Patients with low TSH level showed a higher success rate for levothyroxine (LT4) cessation than patients with high TSH level (1.79 ± 1.08 and 2.76 ± 1.82 mU/L, p < 0.001). Patients who failed to discontinue TST showed a longer maintenance period of TST than patients who succeeded to discontinue TST (54.09 ± 17.44 and 37.58 ± 17.68 months, p < 0.001). Conclusions: Preoperative TSH level and maintenance period of TST are important factors for successful cessation of TST. If TST cessation is planned for patients who are taking LT4 after lobectomy, a higher success rate of TST cessation is expected with low preoperative TSH level and early cessation of LT4.

scholarly journals “Vitamin D Deficiency Is More Common in Women with Autoimmune Thyroiditis: A Retrospective Study”

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Nino Turashvili ◽  
Lali Javashvili ◽  
Elene Giorgadze
Keyword(s):  
Vitamin D ◽  
Retrospective Study ◽  
Vitamin D Deficiency ◽  
Autoimmune Thyroiditis ◽  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Thyroid Autoantibody ◽  
Chronic Autoimmune Thyroiditis ◽  
Antithyroglobulin Antibodies ◽  
Stimulating Hormone

Background. Vitamin D is a hormone that is mainly produced in the skin upon ultraviolet B radiation exposure and has important influence on various organs. In recent years, data have been collected that vitamin D deficiency plays an important role in the development of various nonskeletal diseases, including autoimmune diseases. Chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) is one of the most common organ-specific autoimmune endocrine diseases. It is characterized by increased level of antithyroid peroxidase and/or antithyroglobulin antibodies in blood, which often leads to thyroid dysfunction and structural changes of the gland. There is an opinion that vitamin D deficiency may be considered as an important risk factor for development of chronic autoimmune thyroiditis, but data of various small studies are controversial. Despite the fact that Georgia is a sunny country, vitamin D deficiency is a widespread problem here. Thyroid diseases, including the chronic autoimmune thyroiditis, are also very common in Georgia. The aim of our research was to compare the level of vitamin D between the patients with chronic autoimmune thyroiditis and the healthy subjects. Methods. This retrospective study enrolled subjects, who were 18–70 years old and visited the clinics “Cortex” and “National Institute of Endocrinology” in 2018 or in 2019 from mid-spring to mid-summer. Data of thyroid-stimulating hormone, free thyroxine, antithyroid peroxidase antibodies, antithyroglobulin antibodies, thyroid ultrasonography, and 25(OH) vitamin D were retrospectively analysed based on medical history. In total, data of 1295 patients were collected. The statistical processing of data was performed through the SPSS 20 program. Results. The negative association between thyroid-stimulating hormone, antithyroid peroxidase antibodies, antithyroglobulin antibodies, heterogeneous parenchyma of thyroid gland, and vitamin D was found in women. Statistically significant association was not detected in men. Conclusions. Serum vitamin D is lower in women with autoimmune thyroiditis and primary hypothyroidism. Further studies are needed to evaluate the influence of vitamin D supplementation on thyroid autoantibody positivity or primary hypothyroidism.

Pathogenesis of Marked Pituitary Enlargement and Increased Serum Thyroid-Stimulating Hormone in Primary Hypothyroidism

Thyroid ◽  
2012 ◽  
Vol 22 (1) ◽  
pp. 101-102 ◽  
Author(s):  
Leslie Eiland ◽  
Nelson M. Oyesiku ◽  
James C. Ritchie ◽  
Scott Isaacs ◽  
Adriana G. Ioachimescu
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Pituitary Enlargement ◽  
Stimulating Hormone

scholarly journals Secondary Adrenal Insufficiency and Primary Hypothyroidism: A Complication of Cancer Immunotherapy

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A608-A608
Author(s):  
Helard Andres Manrique
Keyword(s):  
Adrenal Insufficiency ◽  
Brain Mri ◽  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Fluid Replacement ◽  
Thyroid Peroxidase ◽  
Secondary Adrenal Insufficiency ◽  
Protein Activity ◽  
Metabolic Encephalopathy ◽  
Stimulating Hormone

Abstract Background: Immunotherapy has a fundamental role in cancer treatment. However, there have been found secondary effects in different organs due to its use, such as thyroid gland, pituitary gland, and adrenal glands,. This case report describes a case in relation with nivolumab, an antibody that blocks PD1 protein activity, promoting apoptosis Clinical Case: 67 years-old woman, with history of vulvar melanoma since 2016, complicated by pulmonary metastases. She was started with Nivolumab on 2018, every three weeks. After the her last immunotherapy session, she had less appetite, confusion, and incoherent speaking, and was admitted to the hospital In the Emergency, her blood pressure was 70/40mmHg, heart reate was 120 beats per minute. She was treated with fluid replacement. Her initial lab tests showed sodium 115.0 mmol/l(135.0 - 145.0), Chloride 85.9 mmol/l(98.0 - 109.0), Potassium 4.61 mmol/l (3.5 - 5.1), Hemoglobin 12.0, Leucocytes 6500, Platelets 282000, Total Proteins 7.0 (Albumin 4.0 Globulin 3.1), Alanine aminotransferase 10.0U/L (7-56), Aspartate aminotransferase 33.0 U/L (4-50) Creatinine 0.53. Hormonal Profile: T3 (triiodothyronine) 1.33 ng/ml(0.8 - 2.0), T4 (tetraiodothyronine) 7.27 ug/dl (5.1 - 14.1), TSH (thyroid stimulating hormone) ultrasensitive 12.87 uU/mL(0.27 - 4.2), FSH (Follicle stimulating hormone) 26.6mUI/ml, LH (Hormone)10.86 mIU/ml, Prolactin 60.96 ng/ml (6.0 - 29.9), Cortisol (am)0.22 ug/dl (4.2 - 38.4), ACTH (Corticotrophin-releasing hormone) &lt;1.00, Anti TPO (Anti-Thyroid Peroxidase) negative, Glucose: 145 mg /dl, C Peptide: 0.4 ng/ml (0.9 - 7.1). Her brain MRI did not showcerebral edema or metastases. Conclusion: This case concerns metabolic encephalopathy due to severe hyponatremia caused by a secondary adrenal insufficiency (partial hypopituitarism), subclinical hypothyroidism and hyperprolactinemia, related to Nivolumab immunotherapy. Endocrinologists should be aware PD-1 inhibitor’s side effects, of its immunologic modulation mechanisms as they can cause hypophysitis, pituitary pituitary and thyroid dysfunction

scholarly journals Thyroid dysfunction in Human immunodeficiency virus infected patients and their correlation with CD4 count

2021 ◽  
Vol 9 (3) ◽  
pp. 745
Author(s):  
Vipin Porwal ◽  
Rajesh Deshpande ◽  
Aadish Kumar Jain
Keyword(s):  
Human Immunodeficiency Virus ◽  
Thyroid Dysfunction ◽  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Cd4 Count ◽  
Thyroid Disorder ◽  
Cross Sectional ◽  
Secondary Hypothyroidism ◽  
Immunodeficiency Virus ◽  
Stimulating Hormone

Background: The aim of this study was to evaluate the prevalence of thyroid abnormalities in a subset of human immunodeficiency virus positive patients.Methods: This was a cross-sectional prevalence study conducted on adult HIV positive patients. The patients presenting with hypertension, diabetes mellitus, coronary artery disease or thyroid disorder were excluded from the study. An exhaustive medical history and investigation using biochemical, microbiological and radiological tests were performed to confirm the diagnosis. Additionally, tests were done to determine the free T3, T4, thyroid stimulating hormone and CD4 cell count in all the patients.Results: The prevalence of thyroid dysfunction in our study was 45.7%. Various types of thyroid dysfunctions obtained were euthyroid sick syndrome in 18.6%, subclinical hypothyroidism in 11.4%, secondary hypothyroidism in 10% and primary hypothyroidism and hyperthyroidism each in 2.9% cases. As the stage of HIV advanced, there is alteration in the level of thyroid stimulating hormone, FT3 and FT4. A direct correlation was found between FT3 and CD4 counts but no correlation was found between thyroid stimulating hormone and FT4 levels and CD4 counts.Conclusions: A higher prevalence of thyroid dysfunction that was largely asymptomatic was observed in HIV infected patients with significant change in the hormonal levels in patients with low CD4 count. A direct correlation was observed between FT3 hormone level and CD4 count.

Falsely elevated thyroid-stimulating hormone value due to anti-ruthenium antibodies in a patient with primary hypothyroidism: a case report

2017 ◽  
Vol 55 (12) ◽  
Author(s):  
Rocío Suarez Rivero ◽  
Francisco Ponce Lorenzo ◽  
Joaquina Díaz Torres ◽  
José Manuel Ruiz Palomar ◽  
Domingo Orozco-Beltran
Keyword(s):  
Case Report ◽  
Thyroid Stimulating Hormone ◽  
Primary Hypothyroidism ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document